You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Suppliers and packagers for klor-con


✉ Email this page to a colleague

« Back to Dashboard


klor-con

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Upsher Smith Labs KLOR-CON potassium chloride FOR SOLUTION;ORAL 209662 ANDA Upsher-Smith Laboratories, LLC 0245-0360-01 100 PACKET in 1 CARTON (0245-0360-01) / 1 POWDER, FOR SOLUTION in 1 PACKET (0245-0360-89) 2017-10-23
Upsher Smith Labs KLOR-CON potassium chloride FOR SOLUTION;ORAL 209662 ANDA Upsher-Smith Laboratories, LLC 0245-0360-30 30 PACKET in 1 CARTON (0245-0360-30) / 1 POWDER, FOR SOLUTION in 1 PACKET (0245-0360-89) 2017-10-23
Upsher Smith Labs KLOR-CON potassium chloride TABLET, EXTENDED RELEASE;ORAL 019123 NDA Upsher-Smith Laboratories, LLC 0245-5315-01 100 BLISTER PACK in 1 BLISTER PACK (0245-5315-01) / 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK (0245-5315-89) 1986-04-17
Upsher Smith Labs KLOR-CON potassium chloride TABLET, EXTENDED RELEASE;ORAL 019123 NDA Upsher-Smith Laboratories, LLC 0245-5315-11 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0245-5315-11) 1986-04-17
Upsher Smith Labs KLOR-CON potassium chloride TABLET, EXTENDED RELEASE;ORAL 019123 NDA Upsher-Smith Laboratories, LLC 0245-5315-15 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0245-5315-15) 1986-04-17
Upsher Smith Labs KLOR-CON potassium chloride TABLET, EXTENDED RELEASE;ORAL 019123 NDA Upsher-Smith Laboratories, LLC 0245-5316-01 100 BLISTER PACK in 1 BLISTER PACK (0245-5316-01) / 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK (0245-5316-89) 1986-04-17
Upsher Smith Labs KLOR-CON potassium chloride TABLET, EXTENDED RELEASE;ORAL 019123 NDA Upsher-Smith Laboratories, LLC 0245-5316-11 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0245-5316-11) 1986-04-17
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Klor-Con

Last updated: July 30, 2025

Introduction

Klor-Con is a widely prescribed oral potassium chloride supplement used predominantly to treat or prevent hypokalemia—a condition characterized by low potassium levels in the blood. As an essential component in managing electrolyte imbalances, Klor-Con’s global supply chain involves a network of manufacturers, distributors, and raw material suppliers. Ensuring a consistent, high-quality supply requires understanding these suppliers' landscape and the factors influencing their operation.

Market Overview of Klor-Con Supplies

Klor-Con’s active pharmaceutical ingredient (API) is potassium chloride. The formulation is primarily manufactured by producing the API through complex chemical synthesis processes before encapsulation or tablet formulation. The supply chain comprises several key segments:

  1. Raw Material Suppliers: These provide potassium salts and other chemical precursors.
  2. API Manufacturers: These transform raw materials into pharmaceutical-grade potassium chloride.
  3. Finished Drug Manufacturers: These produce the final Klor-Con product, incorporating API into tablets or capsules.
  4. Distributors and Wholesalers: These facilitate distribution to pharmacies, hospitals, and health providers worldwide.

Major Suppliers of Klor-Con API

The core ingredient of Klor-Con, potassium chloride, is produced by several global chemical companies specializing in bulk inorganic chemicals suitable for pharmaceutical applications.

1. Potassium Chemicals Suppliers

  • Olin Corporation: Based in the United States, Olin is a leading producer of chloralkali products, enabling the manufacture of potassium hydroxide and potassium chloride. Their potassium chloride grade is used in both industrial and pharmaceutical contexts, with stringent quality controls [1].

  • Mitsubishi Gas Chemical Company (MGC): A Japanese entity producing high-purity potassium chemicals used in pharmaceutical manufacturing. MGC's potassium chloride supplies are known for their reliability and compliance with pharmacopeial standards [2].

  • AkzoNobel: Dutch multinational providing specialty chemicals, including pharmaceutical-grade potassium chloride, with high purity levels suitable for oral administration [3].

  • Süd-Chemie (now part of Clariant): Supplies potassium salts for medicinal uses, emphasizing consistent quality and supply stability [4].

2. API Manufacturers Specializing in Potassium Chloride

  • PharmaIto (India): An emerging manufacturer producing pharmaceutical-grade potassium chloride for export markets, adhering to Good Manufacturing Practices (GMP) [5].

  • Hubei Bailing Group (China): A significant producer of bulk potassium chloride, supplying raw API that meets international pharmacopeial standards [6].

  • Yara International (Norway): Known globally for fertilizer production, Yara also supplies high-purity potassium salts suitable for pharmaceutical use, often as raw materials for API synthesis [7].

3. Contract Manufacturing Organizations (CMOs)

Some pharmaceutical companies outsource API manufacturing to CMOs with specialized capabilities:

  • Xian Janssen Pharmaceutical Ltd.: Known for consistent API production for global markets.

  • Ji'an Shenmei Pharmaceutical: A Chinese CMO producing potassium chloride API with GMP compliance.

Their involvement ensures a diversified supply chain but also introduces considerations of geopolitical stability and regulatory compliance.

Finished Klor-Con Product Manufacturers

The most prominent firm responsible for branding and distributing Klor-Con extensively is Prinston Pharmaceutical Inc., under the U.S.-based NEOS Clinicals. Their manufacturing facilities are FDA-registered, ensuring quality and regulatory compliance for the U.S. market.

Other companies producing generic versions of potassium chloride supplements include:

  • Torrent Pharmaceuticals (India): Produces both API and finished dosage forms globally [8].

  • Moon Pharmaceuticals (India): Offers potassium chloride tablets, with manufacturing at GMP-certified facilities [9].

  • Aurobindo Pharma (India): Supplies generic potassium chloride tablets utilized worldwide.

Distribution and Supply Chain Considerations

Klor-Con’s supply is affected by geopolitical factors, raw material availability, and regulatory approvals. Notably, supply disruptions have occasionally occurred due to:

  • Trade restrictions impacting raw material imports.

  • Pandemic-related manufacturing delays.

  • Regulatory challenges in different regions affecting API approval and registration.

Emerging Trends and Challenges

  • Supply Chain Resilience: Many companies are increasing inventory buffers and diversifying suppliers to mitigate disruptions.

  • Sustainable Sourcing: A shift towards environmentally responsible extraction and production processes, aligning with global regulations.

  • Regulatory Harmonization: Compliance with international standards, including ICH guidelines, for API quality assurance.

  • Technological Innovations: Use of process analytical technology (PAT) and continuous manufacturing methods improves yields and reduces dependency on scarce raw materials.

Key Players Profile

Company Location Specialization Market Role Notable Certifications
Olin Corporation USA Inorganic chemicals Raw materials supplier GMP, ISO 9001
Mitsubishi Gas Chemical Japan Specialty chemicals Raw material supplier ISO 9001, GMP
Yara International Norway Fertilizers & chemicals Raw material supplier GMP, ISO 9001
Prinston Pharmaceuticals USA Finished drug manufacturing Final product producer FDA, cGMP standards
Aurobindo Pharma India Generics manufacturing Finished API and dosage forms WHO-GMP, USFDA

Regulatory Implications

Suppliers must adhere to stringent regulations to meet regulatory agencies' expectations like the FDA, EMA, and others. Ensuring compliance involves:

  • Certification of GMP compliance

  • Rigorous batch testing

  • Traceability and documentation standards

Any supply chain contamination or quality lapses can lead to drug recalls or supply shortages, emphasizing the importance of sourcing from reliable, compliant suppliers.

Conclusion

The global supply chain for Klor-Con hinges on a limited number of high-quality suppliers of potassium chloride raw materials and APIs. Major contributors include chemical giants like Olin, Mitsubishi Gas Chemical, and Yara International, complemented by a network of API manufacturers operating under stringent regulatory standards. The final formulation production involves specialized pharmaceutical manufacturers with USFDA or equivalent certifications. Supply resilience is critical to meet the ongoing demand for potassium supplements, especially amidst geopolitical and logistical challenges.

Key Takeaways

  • Diversification is vital: Relying on multiple suppliers reduces risk, especially for raw materials like potassium chloride.

  • Regulatory compliance: Ensuring suppliers adhere to GMP and pharmacopeial standards mitigates quality assurance risks.

  • Supply chain transparency: Tracking the origin and manufacturing quality is crucial for risk management and regulatory audits.

  • Emerging markets: Indian and Chinese manufacturers are becoming significant sources, necessitating due diligence on compliance.

  • Strategic stockpiling: Companies should maintain inventory buffers to counteract supply shocks.

FAQs

1. Who are the main raw material suppliers for potassium chloride used in Klor-Con?
Major raw material suppliers include Olin Corporation (USA), Mitsubishi Gas Chemical (Japan), AkzoNobel (Netherlands), and Yara International (Norway). These entities provide pharmaceutical-grade potassium chloride with strict quality standards.

2. Are there regional differences in Klor-Con suppliers?
Yes. In North America and Europe, suppliers like Olin and AkzoNobel dominate, whereas Asian markets increasingly source APIs from Indian and Chinese manufacturers such as Aurobindo Pharma and Hubei Bailing Group, guided by regional approvals and supply chain considerations.

3. What regulatory standards must Klor-Con suppliers meet?
Suppliers must comply with Good Manufacturing Practices (GMP), adhere to pharmacopeial specifications (USP, EP), and obtain certifications from agencies like the FDA and EMA to ensure quality, safety, and efficacy.

4. How is supply chain risk mitigated for Klor-Con?
Companies diversify suppliers, maintain safety stock, enforce strict supplier qualification processes, and monitor geopolitical and logistical developments to prevent shortages or quality issues.

5. Are there alternative sources or substitutes for potassium chloride API?
Currently, potassium chloride is the primary API for Klor-Con; substitutes are limited due to the drug's specificity. However, alternative formulations or salts may be explored, but they require rigorous clinical validation and regulatory approval.


Sources Cited
[1] Olin Corporation Annual Report, 2022.
[2] Mitsubishi Gas Chemical Company, Product Portfolio.
[3] AkzoNobel Chemicals Data Sheet, 2021.
[4] Süd-Chemie (Clariant) Product Profiles, 2020.
[5] PharmaIto API Manufacturing Capabilities, 2022.
[6] Hubei Bailing Group API Quality Certifications, 2022.
[7] Yara International Supply Chain Overview, 2022.
[8] Torrent Pharmaceuticals Corporate Website, 2022.
[9] Moon Pharmaceuticals, Product Listings, 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.